Docoh
Loading...

OTLC Oncotelic Therapeutics

Press releases

From Benzinga Pro
Oncotelic Presenting at BiotechGate Digital Partnering
19 Jan 22
Press Releases
OT-101 is Oncotelic's RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination with IL-2Multiple
Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
5 Jan 22
Press Releases
AGOURA HILLS, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,
Why 2022 Could Open Gangbusters for Covid Stocks (AZN, OTLC, NVAX, PFE, MRNA, MRK, JNJ, BNTX)
3 Jan 22
News, Press Releases
If you think the pandemic is yesterday’s news, think again. One of the nation’s top doctors recently warned that the US could very soon start seeing as many as a million new Covid-19 cases every day due to
ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.
22 Dec 21
Press Releases
AGOURA HILLS, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,
Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
14 Dec 21
Press Releases
AGOURA HILLS, CA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today
Top Ideas in the Small Cap Biotech Space (INMB, OTLC, DVAX, SAVA, ICPT, IMGN)
9 Dec 21
News, Press Releases
Next week the FED will announce if it will double the pace of its bond purchase taper, while also likely hinting at more aggressive rate hikes in 2022. Small cal biotech stocks are back in focus for risk mitigation. The
Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK)
2 Dec 21
News, Press Releases
“Top Biotech Stocks” Wall Street has rebounded today and Dow gaining 600 points. The S&P 500 has added 1% and biotech stocks are back in focus. With the spotlight firmly on Covid variants, it’s
Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma
1 Dec 21
Press Releases
AGOURA HILLS, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
23 Nov 21
Agoura Hills, CA--News Direct--Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that its
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers
16 Nov 21
Press Releases
AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,